Columns
- Specialty Sales in the Global Marketplace
-
James Lennertz, head of global operations at Innovex, discusses the changing role of specialty sales reps.
- Anatomy of a Managed Partnership
-
Michel Abiteboul, vice president of global business development at NovaQuest, outlines various partnering solutions for today’s global pharmaceutical marketplace.
- Safety through Standards
-
Paula Brown Stafford, executive vice president of global data management at Quintiles, discusses how universal data standards can help ensure better patient safety across all phases of clinical research.
- A New Gold Standard for Pricing
-
Dr. John Doyle, practice leader for market access at Quintiles Consulting, introduces the concept of a health economic balance sheet and evidence-based pricing for biopharmaceutical valuation.
- Challenge Accepted
-
Kathleen Marley-Matts, managing director of Quintiles Medical Education, discusses the challenges and opportunities in providing objective CME programming.
- Cultivating Safety
-
Axel Olsen, Ph.D., executive director of global pharmacovigilance and risk management at Quintiles, discusses the need for a new culture of safety in the life sciences sector.
- A Delicate Balance
-
Leslie Cate, vice president of access to patients at Quintiles, explains how building relationships with investigators improves recruitment and reduces clinical trial timelines.
- A New Culture of Safety
-
Dr. Hugo Stephenson, senior executive at Quintiles, encourages pharmaceutical manufacturers, regulators and investigators to embrace a new model for post-marketing studies.
- Safeguarding Subjects
-
Dr. Tim Mant, senior medical adviser at Guy’s Drug Research Unit for Quintiles, explains the importance of protecting volunteer safety in early clinical trials.
- A Guiding Hand
-
As with many aspects of biotechnology, the process of shepherding an emerging product from the laboratory to the patient is full of uncertainties.
Web Exclusives
- Statistical Advantage
-
Gary Shorter, director of biostatistics for Quintiles, talks to Envisage editor Adam Istas about the growing importance of incorporating biostatistical analysis into all stages of drug development.
- Measure for Measure
-
A proposed Health Care Comparative Effectiveness Research Institute in the United States may force the biopharmaceutical industry to emphasize patient outcomes and quality of life issues when developing a new medicinal product.